Isolated hepatocytes stimulation activity on toxic liver failure in experimental study.

Finding of affective treatment methods of acute liver failure (alf), consists one of difficult solving problem in modern hepatology. To day improving liver transplantation methods for the stimulation of regeneration process. Transplantation of liver allogenic isolated hepatocytes in A.L.F.treatment, promotes regeneration morphological capabilities of toxically damaged liver. We used combined enzymatic-mechanical method modified by Korukhov (1983), which let to take up 50-60% of cells from liver mass, 80% from them maintained their morphological structure and functional activity. Experiments were performed on 45 white laboratory rats. Animals were divided into 3 groups. I group of animals (n=20) was the control group, with acute liver failure without treatment, in this group, lethal outcome was 100% in the I group, after CCL4 administration on 5 and 7 days. II group (n=20) included animals who had ALF model and which provides treatment with isolated hepatocytes transplantation. III group of animals were served as donors for isolated hepatocytes uptake. 90% of animals from II group were alive after treatment during 20 days and then their condition was satisfactory. Biochemical and morphological investigation proved that our treatment method induces toxically damaged liver function restoration.

Treatment of toxic liver damage by antihepatocytotoxic serum.

Acute liver failure (ALF) is a broad term that refers to both fulminant hepatic failure (FHF) and subfulminant hepatic failure (or late-onset hepatic failure). The latter term is reserved for patients with liver disease for up to 26 weeks prior to the development of hepatic encephalopathy. Some patients with previously unrecognized chronic liver disease decompensate and present with liver failure; although this technically is not FHF, discerning this at the time of presentation may not be possible (eg, Wilson disease). The objective of present research was to define suitable method for the treatment of toxic damage of the liver. We consider that liver changes occurred in the case of toxic damage can be reversed by administration of antihepatocytotoxic serum which has been developed by us. For this purpose we are going to induce liver toxic damage in the Wister line and investigate the liver regeneration cellular mechanisms after administration of antihepatocytotoxic serum. Experimental investigations were performed on Wister line male rats, animals were divided into four equal groups. In I and II groups we were modelling acute liver failure by injections of hepatotoxic agent CCL4 (I) and performing 70% hepatectomy (II), III group was served as control group, and IV group served as donors for HPCs. The main aspect of our study was to stimulate liver reparative regeneration and by this help to organ function restoration. Performed studies have shown hypertrophy and moderate hyperplasia of hepatocyte organelles. Oval shaped HPCs were also observed, Performed investigations had shown effectiveness of our ALF treatment method in terms of damaged liver function restoration, normalization of morphological picture and biochemical measurements and we hope that administration of antihepatocytotoxic serum developed by us can give a chance to patients with acute liver failure.

Toxic acute liver failure treatment by isolated hepatocytes allotransplantation in experimental.

Acute liver failure treatment nowadays is a common problem in modern hepatology, despite of well studied pathogenesis and treatment modalities, lethality of the disease is still high, and in 21 century in the world's best clinics it accounts to 70-80%. For uptake of isolated hepatocytes we uses the fermental-mechanical method modified by Korukhov (1983) for the treatment of acute liver failure by hepatocyte allotransplantation and to stimulate liver reparative regeneration processes, which gives a chance to liver for the function restoration by replacement of injured hepatocytes with transplanted liver cells. We provide experiments on 45 white laboratory Vistar line rats (150-200gr) which were kept on standard environment, animals were divided into three equal groups: I group (n=20) was served as a control group, in which we provide acute liver failure modelling, by toxic agent (carbontetrachloride CCL4 ) treatment by naso-gastric tube, After acute liver failure modelling, in the II group (n=20) of animals we were conducting liver cell transplantation, III group (n=5) animals were served as donors for isolated hepatocyte uptake. Cell ultrastructure element proliferation clearly seen by morphological evaluation and animals which have acute liver failure had a chance for survival and it may be concluded that our proposed method can be the curative treatment method of acute liver failure in experiment.

Anti-hepato-cytotoxic serum treatment results in acute liver failure.

Only few conditions in medicine are more dramatic or more devastating than acute liver failure, severe liver-cell dysfunction strikes previously well people suddenly, and many of them die. Acute liver failure (ALF) is broad term that refers to both fulminant hepatic failure (FHF) and sub-fulminant hepatic failure (or late-onset hepatic failure). FHF may result from a variety of hepatic disease processes. Viral hepatitis and hepatotoxic drugs are the most common factors inducing severe illness with the loss of hepatic function. Elevated serum concentrations of bacterial endotoxin, tumor necrosis factor-a, and interleukin-1 and interleukin-6 have been found in FHF, but the specific roles of these inflammatory factors are unclear. Numerous causes of FHF exist, but viral hepatitis and acetaminophen overdoses are the most common. The cause remains unknown in as many as 15% of patients. The aim of the study was the evaluation of the clinical course and complications of acute liver failure in experiment, We created an experimental model using hepatotoxic substance (CCL4), which causes centrilobular lesions in liver parenchyma. Nowadays, total or subtotal liver transplantation supposed to be an effective method. The restrictions of this method includes: 1. Donor organ deficit, 2. Post-operative complications, 3. Lifetime immunosuppression, 4. Expensiveness of the method. Our method proposes treatment by anti-hepato-cytotoxic serum, which induces stimulation of hepatocyte regeneration. It consists of vasoactive mediators (nitric oxide, carbon monoxide), activated complement cascade components, immunomodulators, regenerative hepatocytes, membrano-protectors and hepato-stimulator medications.